Statistics on mortality following acute myocardial infarction in 842 897 Europeans
| Autor: | Chris P Gale, Bertil Lindahl, Tomas Jernberg, O A Alabas, Marlous Hall, Mark J. Rutherford, Keith A.A. Fox, Robert West, Harry Hemingway, Adam Timmis, Mar Pujades-Rodriguez |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Time Factors Heart disease Physiology medicine.medical_treatment 030204 cardiovascular system & hematology 0302 clinical medicine Risk Factors Cause of Death Myocardial Revascularization Prevalence Registries UK 030212 general & internal medicine Myocardial infarction Practice Patterns Physicians' Non-ST Elevated Myocardial Infarction Aged 80 and over education.field_of_study Aspirin Middle Aged Treatment Outcome MINAP Practice Guidelines as Topic SWEDEHEART Female Guideline Adherence Cardiology and Cardiovascular Medicine medicine.drug Adult medicine.medical_specialty Adolescent Population Acute myocardial infarction Revascularization Young Adult 03 medical and health sciences Case mix index Physiology (medical) Internal medicine medicine Hospital discharge Humans Healthcare Disparities Mortality education Aged Sweden business.industry Cardiovascular Agents medicine.disease United Kingdom Confidence interval ST Elevation Myocardial Infarction business |
| Zdroj: | Alabas, O A, Jernberg, T, Pujades-Rodriguez, M, Rutherford, M J, West, R M, Hall, M, Timmis, A, Lindahl, B, Fox, K A A, Hemingway, H & Gale, C P 2020, ' Statistics on mortality following acute myocardial infarction in 842 897 Europeans ', Cardiovascular research, vol. 116, no. 1, pp. 149-157 . https://doi.org/10.1093/cvr/cvz197 |
| ISSN: | 1755-3245 0008-6363 |
| DOI: | 10.1093/cvr/cvz197 |
| Popis: | Aims To compare ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) mortality between Sweden and the UK, adjusting for background population rates of expected death, case mix, and treatments. Methods and results National data were collected from hospitals in Sweden [n = 73 hospitals, 180 368 patients, Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)] and the UK [n = 247, 662 529 patients, Myocardial Ischaemia National Audit Project (MINAP)] between 2003 and 2013. There were lower rates of revascularization [STEMI (43.8% vs. 74.9%); NSTEMI (27.5% vs. 43.6%)] and pharmacotherapies at time of hospital discharge including [aspirin (82.9% vs. 90.2%) and (79.9% vs. 88.0%), β-blockers (73.4% vs. 86.4%) and (65.3% vs. 85.1%)] in the UK compared with Sweden, respectively. Standardized net probability of death (NPD) between admission and 1 month was higher in the UK for STEMI [8.0 (95% confidence interval 7.4–8.5) vs. 6.7 (6.5–6.9)] and NSTEMI [6.8 (6.4–7.2) vs. 4.9 (4.7–5.0)]. Between 6 months and 1 year and more than 1 year, NPD remained higher in the UK for NSTEMI [2.9 (2.5–3.3) vs. 2.3 (2.2–2.5)] and [21.4 (20.0–22.8) vs. 18.3 (17.6–19.0)], but was similar for STEMI [0.7 (0.4–1.0) vs. 0.9 (0.7–1.0)] and [8.4 (6.7–10.1) vs. 8.3 (7.5–9.1)]. Conclusion Short-term mortality following STEMI and NSTEMI was higher in the UK compared with Sweden. Mid- and longer-term mortality remained higher in the UK for NSTEMI but was similar for STEMI. Differences in mortality may be due to differential use of guideline-indicated treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|